Bruno C Medeiros1, Megan Othus2, Martin S Tallman3, Zhuoxin Sun4, Hugo F Fernandez5, Jacob M Rowe6, Hillard M Lazarus7, Frederick R Appelbaum8, Selina M Luger9, Mark R Litzow10, Harry P Erba11. 1. Stanford University School of Medicine, Stanford, CA, United States. Electronic address: brunom@stanford.edu. 2. SWOG Statistical Center, Seattle, WA Fred Hutchinson Cancer Research Center, Seattle, WA, United States. 3. Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States. 4. ECOG-ACRIN Statistical Center, Dana-Farber Cancer Institute, Boston, MA, United States. 5. Department of Blood and Marrow Transplant, H. Lee Moffitt Cancer Center, Tampa, FL, United States. 6. Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel; Bruce Rappaport Faculty of Medicine, Technion, Israel Institute of Technology, Haifa, Israel; Department of Hematology, Shaare Zedek Medical Center, Jerusalem, Israel. 7. Department of Medicine, University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH, United States. 8. Fred Hutchinson Cancer Research Center, Seattle, WA University of Washington, Seattle, WA, United States. 9. Abramson Cancer Center of the University of Pennsylvania, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, United States. 10. Division of Hematology and Transplant Center, Mayo Clinic, Rochester, MN, United States. 11. The University of Alabama at Birmingham, Birmingham, AL, United States.
Abstract
PURPOSE: To study whether institutional clinical trial accrual volume affects clinical outcomes of younger (age less than 61 years) patients with acute myeloid leukemia. PATIENTS AND METHODS: We investigated the impact of clinical trial accrual on response rates, early mortality and survival in patients with AML enrolled between 2002 and 2009 into two parallel cooperative group clinical trials SWOG S0106/ECOG-ACRIN E1900. Institutions were classified as low- (LAIs) (≤ 9 enrolled patients) or high-accruing institutions (HAIs) (≥10 enrolled patients). Fisher's exact text and logistic regression analysis were used to analyze the response and early mortality rates. The effect of accrual volume on survival was analyzed by log-rank tests and Cox regression models. RESULTS: A total of 1252 patients from 152 institutions were included in the final analyses. The median clinical trial registrations in HAIs was 19 patients (range, 10 to 92) versus 3 (range, 1 to 9) patients in LAIs. In multivariate analyses, HAIs, as a quantitative covariate, was associated with improved complete remission rates (odds ratio (OR) 1.08, p = 0.0051), but no improvement median overall survival (HR 0.97, p = 0.065) or median event-free (hazard ratio (HR) 0.97, p = 0.05). Early mortality rates were similar between cohorts and academic affiliation had no impact on response rates or survival. CONCLUSION: Clinical trial accrual volume, had an independent, albeit modest, impact on complete remission rates, but not on overall survival and event-free in younger patients with AML.
PURPOSE: To study whether institutional clinical trial accrual volume affects clinical outcomes of younger (age less than 61 years) patients with acute myeloid leukemia. PATIENTS AND METHODS: We investigated the impact of clinical trial accrual on response rates, early mortality and survival in patients with AML enrolled between 2002 and 2009 into two parallel cooperative group clinical trials SWOG S0106/ECOG-ACRIN E1900. Institutions were classified as low- (LAIs) (≤ 9 enrolled patients) or high-accruing institutions (HAIs) (≥10 enrolled patients). Fisher's exact text and logistic regression analysis were used to analyze the response and early mortality rates. The effect of accrual volume on survival was analyzed by log-rank tests and Cox regression models. RESULTS: A total of 1252 patients from 152 institutions were included in the final analyses. The median clinical trial registrations in HAIs was 19 patients (range, 10 to 92) versus 3 (range, 1 to 9) patients in LAIs. In multivariate analyses, HAIs, as a quantitative covariate, was associated with improved complete remission rates (odds ratio (OR) 1.08, p = 0.0051), but no improvement median overall survival (HR 0.97, p = 0.065) or median event-free (hazard ratio (HR) 0.97, p = 0.05). Early mortality rates were similar between cohorts and academic affiliation had no impact on response rates or survival. CONCLUSION: Clinical trial accrual volume, had an independent, albeit modest, impact on complete remission rates, but not on overall survival and event-free in younger patients with AML.
Authors: Smith Giri; Ranjan Pathak; Madan Raj Aryal; Paras Karmacharya; Vijaya Raj Bhatt; Mike G Martin Journal: Blood Date: 2015-05-21 Impact factor: 22.113
Authors: M M Horowitz; D Przepiorka; R E Champlin; R P Gale; A Gratwohl; R H Herzig; H G Prentice; A A Rimm; O Ringdén; M M Bortin Journal: Blood Date: 1992-05-15 Impact factor: 22.113
Authors: Jay P Patel; Mithat Gönen; Maria E Figueroa; Hugo Fernandez; Zhuoxin Sun; Janis Racevskis; Pieter Van Vlierberghe; Igor Dolgalev; Sabrena Thomas; Olga Aminova; Kety Huberman; Janice Cheng; Agnes Viale; Nicholas D Socci; Adriana Heguy; Athena Cherry; Gail Vance; Rodney R Higgins; Rhett P Ketterling; Robert E Gallagher; Mark Litzow; Marcel R M van den Brink; Hillard M Lazarus; Jacob M Rowe; Selina Luger; Adolfo Ferrando; Elisabeth Paietta; Martin S Tallman; Ari Melnick; Omar Abdel-Wahab; Ross L Levine Journal: N Engl J Med Date: 2012-03-14 Impact factor: 91.245
Authors: Jane M Stevens; Finlay Macdougall; Michael Jenner; Heather Oakervee; Jamie Cavenagh; Andrew T Lister Journal: Br J Haematol Date: 2009-02-03 Impact factor: 6.998
Authors: Stephen H Petersdorf; Kenneth J Kopecky; Marilyn Slovak; Cheryl Willman; Thomas Nevill; Joseph Brandwein; Richard A Larson; Harry P Erba; Patrick J Stiff; Robert K Stuart; Roland B Walter; Martin S Tallman; Leif Stenke; Frederick R Appelbaum Journal: Blood Date: 2013-04-16 Impact factor: 22.113